Developing helical peptide antagonists of the growth hormone receptor

This body of work at Ohio University’s Heritage College of Osteopathic Medicine and the Institute for Molecular Medicine and Aging, centers on the design and development of peptide-based antagonists targeting the growth hormone receptor (GHR). The project appears across multiple patent filings listed by the Institute, reflecting a sustained programmatic focus on peptides that inhibit growth hormone action and related therapeutic strategies. Patent entries from 2022 and 2023 explicitly name peptide-based inhibitors of growth hormone action and methods of use, indicating that the team has pursued intellectual property protection for helical peptide antagonists and their applications.

This research emphasis is on antagonizing growth hormone signaling using peptide modalities. The patents cited in the Institute’s portfolio include titles such as “Peptide-Based Inhibitors of Growth Hormone Action and Methods of Use Thereof” (2022, 2023) and related entries that situate peptide antagonists within broader therapeutic strategies, including combination therapies and pegylated growth hormone antagonists.

The work has moved beyond conceptual studies to concrete claims about composition, method, and application that underpin future development and potential commercialization.